Dx Focus: Clinical and Regulatory PCR and Nucleic Acid Testing News | GenomeWeb

Epigenomics said last week that its partner Abbott has launched an in vitro diagnostic test for colorectal cancer in Europe and the Asia/Pacific market.

The test is based on Epigenomics' Septin9 biomarker. Abbott holds non-exclusive worldwide rights to the biomarker under a licensing agreement signed in late 2007. It is optimized for Abbott's RealTime system m2000, an automated PCR platform.

Abbott is marketing the test as the Abbott RealTime mS9 Colorectal Cancer Assay.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.